Sandra Murgas

Title: Sandra Murgas: Innovator in Controlled Release Systems

Introduction

Sandra Murgas is a prominent inventor based in Dresden, Germany. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of controlled release systems for LHRH antagonists. With a total of 2 patents, her work has the potential to impact therapeutic strategies in hormone regulation.

Latest Patents

Murgas's latest patents focus on the preparation of immobilized and activity-stabilized complexes of LHRH antagonists. In her inventions, she aims to develop a release-delaying system for cetrorelix, allowing for controlled release over several weeks. The use of acidic polyamino acids, such as polyglutamic acid and polyaspartic acid, is central to her approach. The preparation of cetrorelix polyamino acid complexes involves combining aqueous solutions, followed by precipitation and drying processes. Animal experiments have confirmed the efficacy of these complexes in achieving testosterone suppression in male rats for over 600 hours. The controlled release of the active compound is influenced by the nature and molecular mass of the polymers used.

Career Highlights

Sandra Murgas is associated with Asta Medica, Aktiengesellschaft, where she continues to innovate in her field. Her work has garnered attention for its potential applications in hormone therapy and drug delivery systems.

Collaborations

Murgas has collaborated with notable colleagues, including Jurgen Engel and Wolfgang Deger, contributing to a dynamic research environment that fosters innovation.

Conclusion

Sandra Murgas is a trailblazer in the development of controlled release systems for pharmaceuticals. Her innovative work in complexation and drug delivery holds promise for future advancements in medical treatments.